Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Articles|July 8, 2026
First Half 2026 Recap: Nephrology
Author(s)Alex Hillenbrand
Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.
Advertisement
Advertisement
The first half of 2026 marked a transformative period in nephrology, with landmark regulatory approvals, evolving clinical practice guidelines, and pivotal phase 3 trial results accelerating a shift toward precision medicine and disease modification. Across
Related to this article
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.
Advertisement
Advertisement